IMS001 / ImStem Biotech - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: ImStem Biotechnology; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Multiple Sclerosis

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: ImStem Biotechnology

Clinical • New P1 trial • CNS Disorders • Multiple Sclerosis

AgeX Therapeutics and ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19 and other causes of ARDS (Businesswire) - "Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS; AgeX Therapeutics, Inc....announced their signing of a non-binding letter of intent for ImStem to obtain...IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease